Designer Benzodiazepines: Another Class of New Psychoactive Substances - PubMed (original) (raw)
Designer Benzodiazepines: Another Class of New Psychoactive Substances
Bjoern Moosmann et al. Handb Exp Pharmacol. 2018.
Abstract
Benzodiazepines have been introduced as medical drugs in the 1960s. They replaced the more toxic barbiturates, which were commonly used for treatment of anxiety or sleep disorders at the time. However, benzodiazepines show a high potential of misuse and dependence. Although being of great value as medicines, dependence to these drugs is a concern worldwide, in part due to overprescription and easy availability. Therefore, the phenomenon of benzodiazepines sold via Internet shops without restrictions at low prices is alarming and poses a serious threat to public health. Most of these compounds (with the exception of, e.g., phenazepam and etizolam) have never been licensed as medical drugs in any part of the world and are structurally derived from medically used benzodiazepines. Strategies of clandestine producers to generate new compounds include typical structural variations of medically used 1,4-benzodiazepines based on structure-activity relationships as well as synthesis of active metabolites and triazolo analogs of these compounds. As they were obviously designed to circumvent national narcotics laws or international control, they can be referred to as "designer benzodiazepines." The majority of these compounds, such as diclazepam, clonazolam, and nitrazolam, have been described in scientific or patent literature. However, little is known about their pharmacological properties and specific risks related to their use. This chapter describes the phenomenon of designer benzodiazepines and summarizes the available data on pharmacokinetics and pharmacodynamics as well as analytical approaches for their detection.
Keywords: Analysis; Designer benzodiazepines; Metabolism; NPS; Pharmacokinetics; Toxicology.
Similar articles
- 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, Papanti D, Schifano F. Orsolini L, et al. Curr Neuropharmacol. 2020;18(9):809-837. doi: 10.2174/1570159X18666200110121333. Curr Neuropharmacol. 2020. PMID: 31933443 Free PMC article. Review. - An expanding world of new psychoactive substances-designer benzodiazepines.
Zawilska JB, Wojcieszak J. Zawilska JB, et al. Neurotoxicology. 2019 Jul;73:8-16. doi: 10.1016/j.neuro.2019.02.015. Epub 2019 Feb 23. Neurotoxicology. 2019. PMID: 30802466 Review. - Designer benzodiazepines' pharmacological effects and potencies: How to find the information.
El Balkhi S, Monchaud C, Herault F, Géniaux H, Saint-Marcoux F. El Balkhi S, et al. J Psychopharmacol. 2020 Sep;34(9):1021-1029. doi: 10.1177/0269881119901096. Epub 2020 Jan 23. J Psychopharmacol. 2020. PMID: 31971477 - Designer benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
Carpenter JE, Murray BP, Dunkley C, Kazzi ZN, Gittinger MH. Carpenter JE, et al. Clin Toxicol (Phila). 2019 Apr;57(4):282-286. doi: 10.1080/15563650.2018.1510502. Epub 2018 Nov 15. Clin Toxicol (Phila). 2019. PMID: 30430874
Cited by
- Notes from the Field: Illicit Benzodiazepines Detected in Patients Evaluated in Emergency Departments for Suspected Opioid Overdose - Four States, October 6, 2020-March 9, 2021.
Aldy K, Mustaquim D, Campleman S, Meyn A, Abston S, Krotulski A, Logan B, Gladden MR, Hughes A, Amaducci A, Shulman J, Schwarz E, Wax P, Brent J, Manini A; Toxicology Investigators Consortium Fentalog Study Group. Aldy K, et al. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1177-1179. doi: 10.15585/mmwr.mm7034a4. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34437520 Free PMC article. No abstract available. - The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity.
Catalani V, Botha M, Corkery JM, Guirguis A, Vento A, Scherbaum N, Schifano F. Catalani V, et al. Pharmaceuticals (Basel). 2021 Jul 26;14(8):720. doi: 10.3390/ph14080720. Pharmaceuticals (Basel). 2021. PMID: 34451817 Free PMC article. - The Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases.
Pérez Orts M, van Asten A, Kohler I. Pérez Orts M, et al. J Anal Toxicol. 2023 Feb 21;47(1):1-25. doi: 10.1093/jat/bkac017. J Anal Toxicol. 2023. PMID: 35294022 Free PMC article. Review. - Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey.
Ritvo AD, Foster DE, Huff C, Finlayson AJR, Silvernail B, Martin PR. Ritvo AD, et al. PLoS One. 2023 Jun 29;18(6):e0285584. doi: 10.1371/journal.pone.0285584. eCollection 2023. PLoS One. 2023. PMID: 37384788 Free PMC article. - 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports.
Orsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, De Berardis D, Papanti D, Schifano F. Orsolini L, et al. Curr Neuropharmacol. 2020;18(9):809-837. doi: 10.2174/1570159X18666200110121333. Curr Neuropharmacol. 2020. PMID: 31933443 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials